par2 Antibody

What is PAR2 and what is its role in inflammatory pathologies?

Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor activated through intramolecular docking of a tethered ligand released by proteases, primarily from the serine protease family . PAR2 is widely expressed throughout human tissues and plays a significant role in inflammatory processes . Its expression in immune system cells correlates with the receptor's ability to mediate cardinal signs of inflammation, and PAR2 is notably up-regulated by inflammatory stimuli .

PAR2 has emerged as a key therapeutic target in chronic inflammatory conditions, particularly inflammatory arthritis. Research by Ferrell and colleagues established that mice lacking the PAR2 gene were protected from arthritis for up to a year . In human studies, increased PAR2 expression has been observed in synovial biopsies from rheumatoid arthritis patients, with activation leading to elevated IL-6 levels . For osteoarthritis, PAR2 activation contributes to synovitis, promotes release of pro-inflammatory cytokines and matrix metalloproteinases, and plays a role in osteophyte formation .

What are the major commercially available PAR2 antibodies and how do they differ?

Several PAR2 antibodies are available for research applications, each with distinct detection capabilities:

• SAM11: Effectively detects ectopic PAR2 in Western blot and both ectopic and endogenous PAR2 in immunocytochemistry and flow cytometry applications .

• C17: Capable of detecting ectopic PAR2 in Western blot and immunocytochemistry, but shows limitations in detecting endogenous PAR2 .

• N19: The most versatile option, successfully detecting both ectopic and endogenous PAR2 across Western blot, immunocytochemistry, and flow cytometry applications .

• H99: Limited utility in Western blot but can detect ectopic PAR2 in immunocytochemistry, though it appears to recognize only a subset of the expressed receptor .

• MAB3949 (Clone #344222): Specifically validated for flow cytometry applications, particularly for detecting PAR2 in human cell lines like HT-29 and PC-3 .

How do different PAR2 antibodies perform across various detection methods?

Performance varies significantly by detection method and antibody:

Western Blot Analysis:

• SAM11 and N19, and to a lesser extent C17, can detect ectopic PAR2 .

• Only N19 reliably detects endogenous PAR2, with other antibodies showing significant non-specific reactivity .

• N19 detects endogenous PAR2 as a broad smear that is sensitive to loss of N-glycosylation .

Immunocytochemistry:

• All four antibodies (SAM11, C17, N19, H99) can detect ectopic PAR2, though H99 appears to detect only a subset of the ectopically expressed receptor .

Flow Cytometry:

• SAM11 and N19 effectively detect both ectopic and endogenous cell surface PAR2 .

• MAB3949 has been validated for detection of PAR2 in human cell lines including HT-29 human colon adenocarcinoma and PC-3 prostate cancer cells .

What controls are essential when using PAR2 antibodies to ensure experimental validity?

When using PAR2 antibodies, implementing appropriate controls is crucial to ensure experimental validity and identify non-specific reactivity . Essential controls include:

• Isotype controls: Use matched isotype control antibodies (e.g., MAB003 for mouse monoclonal antibodies like MAB3949) to assess non-specific binding due to antibody class rather than antigen specificity .

• PAR2-deficient controls: Include PAR2 knock-out cells/tissues or siRNA-mediated PAR2 knockdown samples to identify signals that persist in the absence of PAR2, indicating non-specific reactivity .

• Secondary antibody-only controls: Omit the primary antibody to assess non-specific binding of the secondary antibody .

• Cell type controls: Include known PAR2-expressing cells as positive controls and non-expressing cells as negative controls to validate detection specificity .

The importance of these controls cannot be overstated, as research has demonstrated that Western blot signals detected by SAM11 and C17, and much of the signal detected by N19, against cells endogenously expressing PAR2 can be non-specific .

What is the recommended protocol for PAR2 detection by flow cytometry?

Based on validated approaches, an optimal protocol for PAR2 detection by flow cytometry includes:

• Cell preparation: Generate a single-cell suspension of target cells (e.g., HT-29 or PC-3 cells) .

• Primary antibody staining: Stain cells with an anti-PAR2 antibody (e.g., Mouse Anti-Human PAR2 Monoclonal Antibody, MAB3949) alongside an isotype control antibody (e.g., MAB003) in parallel samples .

• Secondary antibody application: After washing, apply a fluorophore-conjugated secondary antibody, such as Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (e.g., F0102B) .

• Analysis: Compare fluorescence intensity between cells stained with the PAR2 antibody versus the isotype control using flow cytometry .

For HT-29 human colon adenocarcinoma cells, detection can be achieved using Mouse Anti-Human PAR2 Monoclonal Antibody (MAB3949) followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (F0102B) .

How can researchers optimize detection of endogenous versus ectopic PAR2?

Optimizing detection of endogenous versus ectopic PAR2 requires different approaches:

For endogenous PAR2:

• Antibody selection: N19 is most effective for detecting endogenous PAR2 in Western blot, while both SAM11 and N19 are suitable for flow cytometry of endogenous PAR2 .

• Glycosylation considerations: Be aware that N19 detects endogenous PAR2 as a broad smear pattern sensitive to N-glycosylation .

• Signal enhancement: Consider membrane fraction enrichment or immunoprecipitation to concentrate low-abundance endogenous receptor .

For ectopic PAR2:

• Antibody options: SAM11, N19, and C17 can all detect ectopic PAR2 in Western blot, while all four antibodies (including H99) can detect it in immunocytochemistry .

• Expression verification: Always compare detection in transfected versus non-transfected cells to confirm specificity .

• Tagged constructs: Consider using epitope-tagged PAR2 constructs for dual detection options .

What dilutions and conditions are optimal for PAR2 antibody applications?

While optimal dilutions should be determined by each laboratory for each application , general guidelines include:

For Western Blot:

• Initial dilution range: 1:500 to 1:2000

• Consider both reducing and non-reducing conditions, as some antibodies may detect conformations sensitive to reducing agents

For Immunocytochemistry:

• Initial dilution range: 1:50 to 1:500

• Optimize fixation methods as they may affect epitope accessibility

For Flow Cytometry:

• Initial dilution range: 1:50 to 1:200

• For MAB3949, follow validated protocols using HT-29 and PC-3 cells

• Match concentrations of isotype control antibodies precisely

Researchers should perform optimization experiments with a range of antibody dilutions to determine optimal parameters for their specific biological system.

How have PAR2 antibodies contributed to arthritis research?

PAR2 antibodies have been instrumental in elucidating the receptor's role in inflammatory arthritis:

• Expression analysis: PAR2 antibodies have revealed increased receptor expression in synovial biopsies from rheumatoid arthritis patients, with expression correlating with synovial thickness and monocyte infiltration .

• Therapeutic targeting: The PAR2 blocking antibody SAM11 has demonstrated efficacy in inhibiting osteoarthritis progression in murine models where cartilage erosion and subchondral bone formation were markedly reduced compared to controls .

• Treatment response monitoring: PAR2 expression, detected by antibodies, decreases after treatment with anti-rheumatic drugs like methotrexate or sulfasalazine, providing a potential biomarker for treatment efficacy .

• Mechanism elucidation: Antibodies have helped reveal that PAR2 activation contributes to synovitis and promotes the release of pro-inflammatory cytokines and matrix metalloproteinases in osteoarthritis .

What role have PAR2 antibodies played in drug discovery efforts?

PAR2 antibodies have significantly advanced PAR2-targeted drug discovery:

• Structural insights: A PAR2 antibody (Fab3949) was crucial in resolving the first crystal structures of PAR2 in complex with novel non-peptide small molecule antagonists (AZ8838 and AZ3451), revealing two distinct binding pockets and providing critical insights for drug design .

• Target validation: Antibodies have validated PAR2 as a therapeutic target by demonstrating its upregulation and activation in disease states .

• Therapeutic development: Novel antibodies like PAR650097 have been developed as potential therapeutic agents themselves, evaluated in preventing cutaneous allodynia in preclinical models .

• Screening tools: Antibodies provide essential tools for screening compounds that modulate PAR2 activity or expression .

Despite these advances, it has taken almost 25 years for the first PAR2 inhibitor to reach clinical trials, with no PAR2 antagonist yet approved for human use .

How can PAR2 antibodies be used in in vivo research models?

PAR2 antibodies have demonstrated utility in in vivo research applications with specific considerations:

• Dosing protocols: PAR650097, a humanized PAR2 mAb, has been administered intraperitoneally (i.p.) at doses of 30 or 100 mg/kg in mouse models, providing reference points for similar studies .

• Pain research applications: PAR2 antibodies have been evaluated in preventing cutaneous allodynia elicited by PAR2 agonist (SLIGRL) or calcitonin gene-related peptide (CGRP) administration .

• Stress-sensitization models: PAR2 antibodies have been tested in models involving priming with restraint stress followed by challenge with subthreshold doses of TRPA1 agonists like umbellulone .

• Administration timing: In some protocols, PAR2 antibodies are administered as pretreatment prior to the first stimulus (e.g., restraint stress, umbellulone exposure, or SLIGRL/CGRP injection) .

• Controls: Appropriate controls include isotype control proteins (e.g., R347 HULGg1 TM) administered via the same route and at equivalent concentrations .

What novel PAR2 modulators have been developed using antibody-based approaches?

Advances in antibody technology have contributed to the development of novel PAR2 modulators:

• Humanized antibodies: PAR650097 represents a humanized PAR2 monoclonal antibody developed through in vitro affinity maturation via targeted and random mutagenesis of the complementarity determining regions (CDRs) using phage display technology .

• Antibody reformatting: Technologies for converting antibody fragments (e.g., scFv) to full IgG formats have enabled generation of diverse PAR2-targeting molecules with different properties .

• Affinity analysis: Surface plasmon resonance (SPR) techniques have allowed precise measurement of antibody-PAR2 interactions, facilitating development of high-affinity modulators .

• Structure-guided development: Crystal structures of PAR2 in complex with antibody fragments have informed development of novel modulators targeting specific receptor conformations .

What are common sources of non-specific signals when using PAR2 antibodies and how can they be minimized?

Non-specific signals represent a significant challenge when using PAR2 antibodies. Common sources and mitigation strategies include:

• Cross-reactivity with related receptors: PAR2 antibodies may cross-react with other PAR family members or structurally similar GPCRs. To minimize this:

  • Include PAR2-deficient controls

  • Compare detection patterns across multiple antibodies targeting different epitopes

  • Validate with genetic approaches (knockout/knockdown)

• Non-specific binding to other proteins: Western blot signals detected by SAM11 and C17, and much of the signal detected by N19, against cells endogenously expressing PAR2 can be non-specific . To address this:

  • Use stringent blocking conditions

  • Optimize antibody concentrations

  • Include appropriate negative controls in each experiment

• Glycosylation artifacts: N19 detects endogenous PAR2 as a broad smear that is sensitive to N-glycosylation, which can complicate interpretation . Consider:

  • Treating samples with glycosidases when appropriate

  • Using multiple detection methods to confirm results

• Secondary antibody background: Minimize by:

  • Including secondary-only controls

  • Using highly cross-adsorbed secondary antibodies

  • Optimizing secondary antibody dilutions

How should researchers validate a new batch of PAR2 antibody?

When validating a new batch of PAR2 antibody, researchers should implement a comprehensive validation protocol:

• Positive control testing: Test the antibody on cells known to express PAR2 at high levels, such as HT-29 or PC-3 cells .

• Detection in multiple applications: Validate performance across intended applications (Western blot, immunocytochemistry, flow cytometry) to ensure consistent detection .

• Epitope integrity verification: Compare detection pattern with previous batches to ensure the epitope recognition remains consistent .

• Concentration optimization: Perform titration experiments to determine optimal working concentrations for each application .

• Specificity controls: Test against PAR2-deficient samples or after PAR2 knockdown to confirm specificity .

• Cross-validation: Compare results with alternative PAR2 antibodies targeting different epitopes to ensure consistent detection of the receptor .

• Application-specific validation:

  • For flow cytometry: Compare staining between the PAR2 antibody and isotype control

  • For Western blot: Verify expected molecular weight pattern, particularly the glycosylation-dependent broad smear with N19

  • For immunocytochemistry: Confirm expected subcellular localization pattern